Interactive Features

Quiz

Dasatinib and Nilotinib as Second-Line Therapy for CML-CP

04/21/2025

In the real-world analysis comparing dasatinib and nilotinib as second-line therapies in CML-CP, what was the observed MMR rate at 12 months among patients treated with nilotinib?

In the real-world analysis...

04/21/2025

Oncology

Test Your Knowledge

Quiz: Which of the Following is Not a Standard of Care Treatment Option for CML?

09/10/2021

Which of the following is not a current standard of care option for the treatment of patients with CML?

Which of the following is not a...

09/10/2021

Oncology

Test Your Knowledge

Quiz: Which of the Following is Not a Standard of Care Treatment Option for CML?

09/10/2021

Which of the following is not a current standard of care option for the treatment of patients with CML?

Which of the following is not a...

09/10/2021

Oncology

Test Your Knowledge

Quiz: Is the Major BCR-ABL1 Transcript Type Linked to Better Imatinib Response in CML?

04/20/2021

Study findings reported by researchers in Algeria suggest that b3a2 transcript may be tied to ____ (better/worse) responses to imatinib therapy in patients with chronic myeloid leukemia.

Study findings reported by...

04/20/2021

Oncology

Test Your Knowledge

Quiz: Which Treatment is Considered Gold Standard for CML-CP?

03/16/2021

According to experts, which of the following therapy options is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase?

According to experts, which of...

03/16/2021

Oncology

Test Your Knowledge

Quiz: Have TKIs Improved the CML Alternative Treatment Landscape?

02/17/2021

Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.

Prior to experts utilizing...

02/17/2021

Oncology

Test Your Knowledge

Quiz: What Was the Outcome of the ASCEMBL Trial?

12/23/2020

True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug bosutinib, while improving the response rate...

True of False: The ASCEMBL data...

12/23/2020

Oncology

Test Your Knowledge

Quiz: Is Imatinib Considered Gold Standard Frontline Treatment for CML-CP?

11/25/2020

True or False: Imatinib is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase.

True or False: Imatinib is...

11/25/2020

Oncology

Test Your Knowledge

Quiz: Is Additional FISH Testing Info in CML Overlooked?

10/28/2020

True or False: Although FISH testing has been applied to provide definitive information in chronic myeloid leukemia, additional information provided by FISH testing, such as atypical signal patterns that indicate for complicated chromosomal...

True or False: Although FISH...

10/28/2020

Oncology

Test Your Knowledge

Quiz: Which Clinical Trial Approved the Use of Imatinib for CML?

09/25/2020

Which clinical trial displayed results that were in favor of imatinib, both in terms of efficacy and tolerability, for chronic myeloid leukemia?

Which clinical trial displayed...

09/25/2020

Oncology

Recent News

News

Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise

01/29/2026

Stephanie Holland

Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...

Results from a real-world...

01/29/2026

Oncology

News

Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer

01/29/2026

Emily Estrada

The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.

The addition of elenagen to...

01/29/2026

Oncology

News

Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma

01/28/2026

Stephanie Holland

Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.

Results from the phase 1/2...

01/28/2026

Oncology

News

Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer

01/27/2026

Gina Tomaine

Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.

Antibody-based therapies are...

01/27/2026

Oncology

News

Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial

01/27/2026

Emily Estrada

Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.

Tucatinib plus trastuzumab...

01/27/2026

Oncology

News

TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC

01/27/2026

Emily Estrada

A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.

A TOMOX-bevacizumab combination...

01/27/2026

Oncology

News

ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC

01/27/2026

Gina Tomaine

A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.

A translational study identified...

01/27/2026

Oncology

News

CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT

01/26/2026

Gina Tomaine

Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.

Systemic CSF-1R inhibition...

01/26/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer

01/22/2026

Stephanie Holland

Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...

Results from the phase 3...

01/22/2026

Oncology

News

Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer

01/21/2026

Stephanie Holland

Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...

Results from a multicenter,...

01/21/2026

Oncology